#CROI

Condomless receptive intercourse, ulcerative STIs, fisting and sharing sex toys are all linked with acquiring hepatitis C among HIV-posi...

Percentage of pregnant or breastfeeding mothers in three sub-Saharan African nations have viral loads high enough to pass HIV on babies.

HIV launches an immediate assault on the gut after infection, spurring inflammation and causing other damage that even very early antiretrovir...

A so-called TLR7 agonist has shown promise in its ability to wake infected cells from a dormant state and cause them to produce HIV.

People with HIV may experience body fat gains as a consequence of the virus rather than antiretrovirals.

New research underscores the great potential of Truvada as pre-exposure prophylaxis for preventing HIV among gay and bisexual men.

The smoking cessation aid Chantix works about as well among people with HIV as those without, although less than a fifth of those taking the d...

Researchers presented results from various studies on hepatitis C treatment and care at a medical conference in Seattle.

Levels of Selzentry (maraviroc) in vaginal and rectal tissues following a single dose were not high enough to be effective as PrEP in a recent...

People with HIV who take Viread, Norvir, Reyataz or Norvir-boosted Kaletra are at increasing risk of kidney disease over time.

As PrEP use in San Francisco rises, researchers have projected that further increases could take a sizeable bite out of the city’s already..

For those coinfected with HIV, waiting to begin hepatitis C treatment until liver damage progresses raises the risk of liver-related complicat...

South Africa’s HIV-positive population has relatively low rates of engagement in health care and viral suppression, paralleling similarly low...

People who coinfected with HIV and hepatitis C looking to take the HCV drug Olysio may need to change HIV medications to avoid drug-drug...

NY City is better linking people diagnosed with HIV into prompt medical care, as well as getting them treated and to full viral suppression.

Harvoni yielded a 96 percent cure rate among people with genotype 1 of hepatitis C, as well as a small number of those with genotype 4.